Tri-functional antibody to OSCC and complement regulatory proteins

点击翻译按钮获取中文摘要

We have studied the anti-tumor activities of an anti-MUC1 antibody with oral squamous cell carcinoma (OSCC). We hypothesized the inhibition of complement regulatory proteins (CRPs) could enhance anti-tumor activity. Therefore, that reversing the effects of complement regulatory proteins expressed on a tumor cell surface will allow more effective immune-mediated clearance of tumor cells and improve prospects for successful immunotherapy. When the complement-dependent cytotoxicity was compared treatment with both an anti-MUC1 mAb and inhibiting mAbs of CD55 or CD59 to an anti-MUC1 mAb alone, a 2- to 3-fold increase in C-dependent cell lysis was observed, respectively. It was also proposed to produce the tri-functional antibodies recognized both MUC1 and CRPs. We done to produce the expression vectors of tri-functional antibodies.